# Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy

> **NCT07461220** · PHASE1,PHASE2 · RECRUITING · sponsor: **Integrative Research Laboratories AB** · enrollment: 75 (estimated)

## Conditions studied

- PARKINSON DISEASE (Disorder)
- Apathy
- Safety

## Interventions

- **DRUG:** IRL757
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07461220
- **Lead sponsor:** Integrative Research Laboratories AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-18
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07461220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07461220, "Safety and Tolerability of IRL757 in Participants With Parkinson's Disease and Apathy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07461220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*